e13035 Background: T-DXd is a HER2 antibody–drug conjugate. It improves patient
outcomes and is FDA approved for the treatment of patients with Her-2 positive and Her-2 …

T rastuzumab deruxtecan (T-DXd) is an antibody–drug conjugate widely used in human
epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC), based …

1077 Background: In the clinical trial setting, T-DXd improves survival for patients with
HER2+ and HER2-low metastatic breast cancer (MBC), and has also shown preliminary …

Abstract Background: Trastuzumab Deruxtecan (T-DXd) is an antibody-drug conjugate
originally approved for use in patients with HER2–positive metastatic breast cancer (MBC) …

TPS1096 Background: HER2-targeted therapies have improved survival in patients (pts)
with HER2+ advanced/metastatic breast cancer (mBC) but challenges remain, including …

Background: The HER2-targeted antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-
DXd) demonstrated efficacy in heavily pretreated HER2-over-and HER2-low expressing …

Trastuzumab deruxtecan (T-DXd) is an anti-HER2 (human epidermal growth factor receptor
2) antibody-drug conjugate which has previously shown efficacy in patients with HER2 …

This is a summary of the article discussing the results of the DESTINY-Breast01 study
originally published in the New England Journal of Medicine. The DESTINY-Breast01 study …

Purpose: Trastuzumab deruxtecan (T-DXd) has been available since April 2021 via the
Cancer Drugs Fund for patients with unresectable or metastatic HER2-positive breast cancer …

Abstract Background Trastuzumab deruxtecan (T-DXd) demonstrated unprecedented
efficacy in patients with pretreated HER2+ metastatic breast cancer (mBC). However, few …